Hypocretin/orexin prevents recovery from sickness
- Authors:
- Susumu Tanaka
- Hiromi Toyoda
- Yoshiko Honda
- Yasuko Seki
- Takeshi Sakurai
- Kazuki Honda
- Tohru Kodama
View Affiliations
Affiliations: Sleep Disorders Project, Department of Psychiatry and Behavioral Science, Tokyo Metropolitan Institute of Medical Science, Tokyo 156‑8506, Japan, Department of Molecular Neuroscience and Integrative Physiology, Faculty of Medicine, Kanazawa University, Kanazawa, Ishikawa 920‑8640, Japan
- Published online on: July 17, 2015 https://doi.org/10.3892/br.2015.491
-
Pages:
648-650
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Sickness behavior is defined as states of lethargy, depression, anxiety, loss of appetite, hypersomnia, hyperalgesia, reduction of grooming and failure to concentrate that can be induced by inflammatory diseases, such as infections and cancer. Recent findings revealed that the lipopolysaccharide (LPS) injection causes lethargy as a consequence of the inhibition of hypocretin signaling. The hypocretin system maintains the vigilance state in various physiological processes. In order to investigate the sleep arousal system against sickness behavior, LPS‑induced sickness behavior was examined in hypocretin‑ataxin‑3 transgenic mice, whose hypocretin neurons were postnatally ablated. Sleep‑wake activity was determined following the administration of LPS at Zeitgeber time (ZT) 8.0 in ataxin‑3 transgenic mice, and the age‑, gender‑matched wild‑type littermates. LPS injection induced increases in non‑rapid eye movement (REM) sleep in the matched wild‑type littermates. In addition, a further increase in periods of sleep according to the loss of hypocretin neurons was identified in the ataxin‑3 transgenic mice. A marked reduction of awakening during ZT12‑ZT18 was observed as expected following LPS injection in the mouse lines. The increase in the period of non‑REM sleep was not observed on the next day following LPS administration in either of the mouse lines. Complete recovery of physical activity was not observed in the matched wild‑type littermates. Ataxin‑3 transgenic mice recovered their physical activity to the same level as that on the first day before LPS administration. These results suggest the possibility that a faster recovery is the result of deeper resting according to the absence of hypocretin neurons, as ataxin‑3 transgenic mice demonstrated more non-REM sleep.
View References
|
1
|
Grossberg AJ, Zhu X, Leinninger GM,
Levasseur PR, Braun TP, Myers MG Jr and Marks DL:
Inflammation-induced lethargy is mediated by suppression of orexin
neuron activity. J Neurosci. 31:11376–11386. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
de Lecea L and Sutcliffe JG: The
hypocretins and sleep. FEBS J. 272:5675–5688. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sakurai T: The neural circuit of orexin
(hypocretin): Maintaining sleep and wakefulness. Nat Rev Neurosci.
8:171–181. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mieda M, Willie JT, Hara J, Sinton CM,
Sakurai T and Yanagisawa M: Orexin peptides prevent cataplexy and
improve wakefulness in an orexin neuron-ablated model of narcolepsy
in mice. Proc Natl Acad Sci USA. 101:4649–4654. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Harris GC and Aston-Jones G: Arousal and
reward: A dichotomy in orexin function. Trends Neurosci.
29:571–577. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hara J, Beuckmann CT, Nambu T, et al:
Genetic ablation of orexin neurons in mice results in narcolepsy,
hypophagia and obesity. Neuron. 30:345–354. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Peyron C, Faraco J, Rogers W, et al: A
mutation in a case of early onset narcolepsy and a generalized
absence of hypocretin peptides in human narcoleptic brains. Nat
Med. 6:991–997. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chemelli RM, Willie JT, Sinton CM, et al:
Narcolepsy in orexin knockout mice: Molecular genetics of sleep
regulation. Cell. 98:437–451. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Radulovacki M, Virus RM, Djuricic-Nedelson
M and Green RD: Adenosine analogs and sleep in rats. J Pharmacol
Exp Ther. 228:268–274. 1984.PubMed/NCBI
|
|
10
|
Morrow JD and Opp MR: Diurnal variation of
lipopolysaccharide-induced alterations in sleep and body
temperature of interleukin-6-deficient mice. Brain Behav Immun.
19:40–51. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cao M and Guilleminault C: Hypocretin and
its emerging role as a target for treatment of sleep disorders.
Curr Neurol Neurosci Rep. 11:227–234. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Roecker AJ and Coleman PJ: Orexin receptor
antagonists: Medicinal chemistry and therapeutic potential. Curr
Top Med Chem. 8:977–987. 2008. View Article : Google Scholar : PubMed/NCBI
|
